SPRO Spero Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SPRO

Price (delayed)

$1.24

Market cap

$72.21M

P/E Ratio

8.86

Dividend/share

N/A

EPS

$0.14

Enterprise value

$23.48M

?
Relative Growth: Rel. Growth: 31
Relative Strength: Rel. Strength: 4
Relative Valuation: Rel. Valuation: 96
Relative Profitability: Rel. Profitability: 98

SmartPros Ltd. (SmartPros) provides learning and training solutions for specific markets, including accounting/finance, legal, engineering, securities, and insurance, as well as banking and information technology professionals. SmartPros' primary products are ...

Highlights
The debt has declined by 43% year-on-year and by 17% since the previous quarter
The net income has soared by 114% YoY but it has plunged by 52% from the previous quarter
The EPS has surged by 114% year-on-year but it has declined by 48% since the previous quarter
SPRO's revenue is down by 23% from the previous quarter and by 3.3% YoY
The gross profit has contracted by 23% from the previous quarter and by 3.3% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://sperotherapeutics.com
Peers: FC IBM DV

Key stats

What are the main financial stats of SPRO

SPRO stock price

How has the Spero Therapeutics stock price performed over time
Intraday
4.2%
1 week
-2.36%
1 month
-43.12%
1 year
-35.92%
YTD
-46.78%
QTD
-43.89%

Financial performance

How have Spero Therapeutics's revenue and profit performed over time
Revenue
$47M
Gross profit
$47M
Operating income
$6.03M
Net income
$7.38M
Gross margin
100%
Net margin
15.7%
The net income has soared by 114% YoY but it has plunged by 52% from the previous quarter
The net margin has surged by 114% year-on-year but it has declined by 37% since the previous quarter
SPRO's operating margin has surged by 111% year-on-year but it is down by 42% since the previous quarter
Spero Therapeutics's operating income has soared by 110% YoY but it has plunged by 55% from the previous quarter

Price vs fundamentals

How does SPRO's price correlate with its fundamentals

Growth

What is Spero Therapeutics's growth rate over time

Valuation

What is Spero Therapeutics stock price valuation
SPRO P/E details
P/E
8.86
P/B
1.62
P/S
1.53
EV/EBIT
3.07
EV/EBITDA
3.07
EV/Sales
0.5
The EPS has surged by 114% year-on-year but it has declined by 48% since the previous quarter
The price to book (P/B) is 44% less than the last 4 quarters average of 2.9 and 30% less than the 5-year quarterly average of 2.3
The equity has increased by 35% year-on-year but it has declined by 16% since the previous quarter
SPRO's P/S is 74% below its 5-year quarterly average of 5.8 and 36% below its last 4 quarters average of 2.4
SPRO's revenue is down by 23% from the previous quarter and by 3.3% YoY

Efficiency

How efficient is Spero Therapeutics business performance
SPRO's ROIC has soared by 154% YoY and by 37% QoQ
The return on assets has surged by 123% year-on-year but it has declined by 50% since the previous quarter
The return on sales has surged by 115% year-on-year but it has declined by 36% since the previous quarter
Spero Therapeutics's ROE has soared by 113% YoY but it has plunged by 54% from the previous quarter

Dividends

What is SPRO's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Spero Therapeutics financials performed over time
SPRO's total liabilities has dropped by 71% year-on-year but it is up by 41% since the previous quarter
SPRO's quick ratio has surged by 55% year-on-year but it is down by 41% since the previous quarter
The debt is 95% smaller than the equity
The debt to equity has plunged by 55% YoY
The debt has declined by 43% year-on-year and by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.